// archives

Congressos e Eventos

This category contains 14 posts

II Simposio Regional de Atualização em Terapia Regenerativa

A primeira edição do Simpósio Regional de Atualização em Terapia Regenerativa com Células-tronco foi realizada entre os dias 28 a 30 de junho de 2007, nas dependências do Hotel Itaimbé, em Santa Maria, Rio Grande do Sul. Naquela oportunidade, as pesquisas com células-tronco, ainda que incipientes, começavam a despertar o interesse da sociedade civil organizada, que cada vez mais voltava seus olhos para a chamada Medicina Regenerativa, com especial atenção para os avanços da Terapia Celular, dentro deste ramo das ciências biomédicas.
Criava-se uma expectativa muito grande em torno da temática e quais seriam as possibilidades de uso para esta terapia e suas reais chances de sucesso para o tratamento de um grande número de doenças. Por este motivo, pesquisadores do Laboratório de Cirurgia Experimental (LACE) da Universidade Federal de Santa Maria (UFSM), julgaram necessário a realização de um evento que reunisse pesquisadores de renome nacional para trazer aos docentes, discentes e público em geral da região sul do nosso país, um panorama preciso sobre o andamento das pesquisas e especulações sobre o futuro da Terapia Celular.
Passado mais de quatro anos da primeira edição, avalia-se a necessidade da realização de uma nova edição deste Simpósio, visto que muitos conceitos e teorias sobre a utilização de células-tronco nas diversas doenças humanas e animais mudaram muito nesta quase meia década. Novas pesquisas estão em andamento, aplicações clínicas já são realizadas em pacientes humanos e animais, novos conceitos e teorias foram formulados, em detrimento de idéias que caíram em desuso neste último período. Todos estes avanços e mudanças justificam a realização de uma segunda edição deste evento.
Por este motivo, entre os dias 21 e 24 de novembro de 2011, o Laboratório de Cirurgia Experimental (LACE) da Universidade Federal de Santa Maria (UFSM) terá a honra de promover o II SIMPÓSIO REGIONAL DE ATUALIZAÇÃO EM TERAPIA REGENERATIVA COM CÉLULAS-TRONCO (II SITERCEL), na cidade de Santa Maria, Rio Grande do Sul. O Hotel Itaimbé será novamente a sede deste Simpósio e, durante este período, pesquisadores, acadêmicos de graduação e pós-graduação dos cursos da área da saúde e público em geral, da região sul do país, serão brindados com a participação de palestrantes de diversas regiões do Brasil, todos pesquisadores de renome internacional e com vasta experiência em projetos de pesquisa envolvendo a Terapia Celular.
Sejam todos bem-vindos e tenham uma ótima estada na Cidade Universitária do Rio Grande do Sul, são os votos da Comissão Organizadora do II SITERCEL.
Professor Dr. Ney Luis Pippi, presidente da Comissão Organizadora.

Seminário da Anvisa vai discutir terapias celulares

No mês de outubro, entre os dias 17 e 18, a Anvisa organiza um seminário técnico para discutir a criação de um órgão interinstitucional para regular as terapias que resultem do cultivo, seleção e manipulação de células.

O assunto tem despertado interesse em profissionais da saúde, entretanto o desenvolvimento de terapias celulares esbarra em entraves, como a falta de regulamentação e de parâmetros éticos.

“Precisamos definir um marco regulatório, a partir do qual estará valendo a exploração de produtos derivados de células, inclusive de células-tronco, sejam adultas ou embrionárias”, disse o gerente de Tecidos, Células e Órgãos da Anvisa, Daniel Coradi.

Entre os assuntos a ser levantado no seminário, são todas as decisões que regulamentam o assunto. A Anvisa disponibilizou 200 vagas para o seminário, interessados devem enviar e-mail para cerimonial@anvisa.gov.br. A inscrição é gratuita.

“Frente à tamanha polêmica envolvendo terapia celular, é importante desde já definir o que pode e o que não pode ser feito, mesmo para nortear as pesquisas na direção correta em busca de tratamentos efetivos”, destaca o farmacêutico, tutor do Portal Educação, Ronaldo de Jesus Costa.

Milton Artur Ruiz

Transplante e uso de células-tronco será tema de Congresso Brasileiro de TMO

Doenças auto-imunes podem ser tratadas com nova terapia celular que poderá propiciar melhor qualidade de vida aos pacientes com diabetes tipo 1, lúpus eritematoso sistêmico e esclerose múltipla

O XV Congresso da Sociedade Brasileira de Medula Óssea, que acontece de 11 a 14 de agosto no Centro de Convenções do Hotel Windsor Barra, no Rio de Janeiro, terá como um dos temas o uso de células-tronco hematopoéticas (CTH), capazes de produzir tecidos de ossos, cartilagem e músculo cardíaco.

Nos últimos anos, foram desenvolvidas várias pesquisas relacionadas ao uso dessas células no tratamento de algumas doenças auto-imunes. O tratamento é feito por meio do transplante autogênico de células tronco hematopoéticas (TACTH) ou seja utilizando células do próprio paciente. Algumas doenças como diabetes tipo 1, lúpus e esclerose múltipla, já estão sendo tratadas com o TCTH em grandes centros como Rio de Janeiro e São Paulo. Estudos comprovaram, por exemplo, que pessoas que sofriam de diabetes tipo 1, tiveram melhora significativa, deixando até de utilizar a insulina por vários anos.

Os estudos sobre o transplante de medula óssea (TMO) para outras enfermidades não hematológicas ou neoplásicas, de acordo com presidente do Congresso, Dr. Luis Fernando Bouzas, são casos sem grande perspectiva de melhora com os tratamentos que existem hoje, como a esclerose múltipla e sistêmica. “A possibilidade com o transplante é de proporcionar uma qualidade de vida completamente diferente aos pacientes, pois o transplante aumenta a sobrevida, estabiliza a enfermidade e reduz a necessidade de medicamentos por muitos anos”, afirma o especialista.

Medicina Regenerativa: novos horizontes

A medicina regenerativa, que faz uso de CTH e Mesenquimais (CTM) para a recuperação de certos tecidos danificados, é outra novidade que será tratada no Congresso. Consiste em fazer aplicações de CTH/CTM diretamente sobre o tecido lesado, como o coração após um infarto ou comprometido com doença de Chagas. A Universidade de São Paulo (USP) tem utilizado a injeção de CTH diretamente em ossos fraturados, onde foi constatado uma recuperação muito mais rápida do paciente, bem como em doenças neurológicas e vasculares, porém ainda sob protocolos de pesquisa.

Apesar de se encontrar em fase experimental, já existem pedidos de autorização para que os procedimentos com CTH/CTM entrem na rotina do SUS – Sistema Único de Saúde. Estes procedimentos encontram-se em fase de discussão em grupos de trabalho da Agência Nacional de Vigilância Sanitária (ANVISA) e dos Ministérios da Ciência e Tecnologia e Saúde, cuja conclusão será a normatização/regulamentação do preparo das células para o uso terapeutico.

Além do TCTH e da Terapia celular com CTH e CTM, outros temas importantes serão discutidos no Congresso:
• A seleção ideal de doadores no tratamento de doenças hematológicas malignas;
• O uso das células do Sangue de Cordão Umbilical;
• Simpósio de HLA e Doenças;
• Biologia da Célula Tronco normal e tumoral;
• TCTH – Tendências dos últimos 30 anos;
• TCTH em Pediatria;
• Transplante alogênico em pacientes idosos;
• Prevenção e Atuação nos Acidentes nucleares e radioativos;
• Aspectos Multidisciplinares do TCTH;
• Principais complicações do TCTH e seu manejo;
• Apresentação de resultados e propostas futuras dos Centros de TCTH Nacionais.

O encontro tem parceria com o ISCT (International Society for Cellular Therapy ou Sociedade Internacional para Terapia Celular) e terá a participação de entidades co-irmãs como a Associação Brasileira de Hematologia e Hemoterapia (ABHH), Associação Brasileira de Histocompatibilidade (ABH) e Sociedade Brasileira de Oncologia Pediátrica (SOBOPE).

Também será realizada reunião dos representantes Latino Americanos sob a chancela da Worldwide Bone Marrow Transplantation (WBMT ) e da SBTMO, no sentido de organizar uma possível Sociedade Latino Americana de TCTH, fortalecendo o desenvolvimento da atividade em nosso continente.

Agenda
XV Congresso da Sociedade Brasileira de Transplante de Medula Óssea – SBTMO
Data: 11 a 14 de agosto de 2011
Local: Centro de Convenções do Hotel Windsor Barra
Endereço: Avenida Lucia Costa, 2630 – Barra da Tijuca – Rio de Janeiro – RJ

Informação Assessoria de imprensa.

Milton Artur Ruiz

Osasco recebe campanha de doação de medula óssea

A Associação da Medula Óssea do Estado de São Paulo – Ameo – faz Campanha sábado (23/07) com o propósito de incentivar o cadastro de doadores voluntários no registro nacional – Redome.
A Campanha será na Escola Estadual Professora Lucy Anna Carroso Latorre, das 10h às 18h e visa informar e sensibilizar a população para se tornar um doador, além de conscientizar sobre a doação de medula óssea, destacar as dificuldades dos pacientes que necessitam do transplante, explicar as formas de doação e informar os pré-requisitos para se tornar um doador voluntário.

O transplante de medula óssea é a esperança de cura para milhares de portadores de leucemias e outros tipos de doenças do sangue. Para se cadastrar como doador basta ter entre 18 e 54 anos de idade e bom estado de saúde, não ser usuário de drogas e não ter nenhum tipo de doença infecciosa transmissível pelo sangue. Não é necessário estar em jejum.

Durante a coleta, o doador deverá estar munido de documentos pessoais (RG e CPF) para a realização do cadastro e logo após, será feita a coleta de uma pequena quantidade de sangue (10ml) para o exame de compatibilidade, que identifica as características genéticas do doador.
Os dados serão cruzados constantemente com os dos pacientes que precisam de transplante de medula óssea constantemente. Se o doador for compatível com algum paciente, outros exames de sangue serão necessários. Após a compatibilidade ser constatada, o doador é consultado para confirmar a doação.

Cadastramento de doadores será feito pela Ameo das 10h às 18h

Ameo – Campanha de Cadastro de Doação de Medula Óssea / Osasco
Dia: 23/07/2011
Hora: das 10h às 18h
Local: E.E. Profª Lucy Anna Carrozo Latorre – Rua Misótis, 431/ Jardim das Flores. Osasco/SP.

Colaboração de Assessoria de Imprensa.

II Simpósio de Citometria de Fluxo

Auditório Aggeu Magalhães
10/12 de outubro de 2011 Recife -Pernambuco , Brasil
Informações: http://scf2.cpqam.fiocruz.br / Simposio.Citometria@cpqam.fiocruz.br

Inscrições pelo site: www.nacc.org.br

Programação

10 de Outubro (Segunda-feira)
8h – 9h – Entrega do Materia
9h – 9h15 – Abertura
Dra. Norma Lucena Cavalcanti Licinio da Silva
Fiocruz/PE & CEHOPE/IMIP

9h15–10h15 – Palestra: Princípios básicos da citometria de fluxo.
Fundamentos da citometria de fluxo: Lasers, Óptica e Dinâmica de Fluídos.
Rodrigo Pestana – BD Biosciences

10h15- 11h15 – Palestra: Caracterização de leucemia do adulto pela citometria de fluxo.
Dr. Edgar Rizzatti – Laboratório Fleury, São Paulo

11h15-12h15 – Palestra: Characterization of childhood
acute leukemia by flow cytometry- technical
aspects.
Dra. Elaine Coustan-Smith, St. Jude,
Memphis/USA & Singapore

12h15 – 12h30 – Perguntas – Resumo Módulo da Manhã

12h30–13h30 – Almoço

13h30 – 14h30 – Palestra:Overview of Minimal Residual
Disease (MRD) in B lineage ALL – normal
differentiation and choice of antibody panels
Dra. Elaine Coustan-Smith, St. Jude,
Memphis/USA & Singapore

14h30 – 15h30 – Palestra: Clinical Significance of MRD
Studies in Acute Lymphoblastic Leukemia
Dr. Dario Campana, St.Jude, Memphis/USA
& Singapore

15h30 – 16h30 – Palestra: Clinical Significance of MRD
Studies in Acute Myeloid Leukemia
Dr. Dario Campana, St.Jude, Memphis/USA
& Singapore

16h30 – 17h – Unidade multiusuario de Citometria de fluxo.
Dra. Norma Lucena Cavalcanti Licinio da Silva
Fiocruz/PE & CEHOPE/IMIP

17h-17h30 – Perguntas- Resumo Módulo da Tarde

11 de Outubro (Terça-feira)

9h–10h – Palestra: Aplicação do CBA na avaliação imune do
Paciente.
Representante da Becton Dickinson.

10h-11h–Palestra: Transplante de células progenitoras
hematopoiéticas.
Dr. Júlio César Voltarelli – Hemocentro de
Ribeirão Preto /SP

11h-12h – Palestra: Métodos de caracterização de
pacientes doadores e receptores de células tronco
hematopoiéticas e quantificação de células tronco
hematopoiéticas em concentrado de leucoaférese
e cordão umbilical.
Dra. Patricia Vianna, Hemocentro de Ribeirão
Preto/SP

12h- 13h – Almoço

13h–14h– Palestra: Caracterização do Complexo MHC no transplante.
Dr Eduardo Donadi, FMRP – USP Ribeirão Preto

14h–15h – Palestra

14h-15h30 – Análise de Ciclo Celular pela Citometria de Fluxo.
Representante da Becton Dickinson

15h30 – 16h30 – Mesa Redonda: Aplicações em citometria tema livre 10 min

16h30 –17h30 – Encerramento. Entrega dos certificados

12 de Outubro atividade prática para os selecionados

Nederland 2011 – 17th ISCT Annual Meeting– Rotterdam – Workshops

Os wokshops ocorreraram durante o ISCT Annual Meeting, e os textos disponibizados pela organização do congresso em inglês, estão aqui disponibilizados ou podem ser acessados no site: www.cellularatherapy2011.com

Workshop 1: Ex-Vivo Expansion (Joint Session with EBMT)
Thursday 5/19/2011
Time: 3:30pm – 5:00pm

Ex-vivo expansion represents the “Holy Grail” of stem cell biologists, and a hope to improve results of human stem cell transplantation, especially in situations where available grafts contain limited numbers of hematopoietic progenitors, such as in cord blood transplantation. Initial attempts mostly relied on the use of cytokine combinations, but have largely failed to produce clinically relevant results; the production of differentiated, mature and functional cells may however be feasible on a large scale and find applications within a near future in selected situations. Next generations of pre-clinical and clinical trials currently explore the possibility to manipulate other types of signals that more directly regulate stem cell behavior such as Notch. Recent results in murine models and in human trials suggest that such targets can be identified, and that their modulation can result in significant changes in hematopoietic stem cell activity associated with potential clinical benefits (enhanced hematopoietic recovery). The workshop will illustrate some of the recent developments in this field.
________________________________________
Workshop 2: Mesenchymal Stem/Stromal Cells and Tumors
Thursday 5/19/2011
Time: 3:30pm – 5:00pm

While large amount of data suggested the role of MSC as regenerative tools by differentiation, new intriguing insights are progressively indicating how these cells may be additionally acting in releasing relevant amounts of largely unknown bio-molecules to beused in different contexts of biomedicine.
Based on this background this workshop will address how wild type or gene modified MSC can be used as bio-molecules factories against cancer mimicking immune effectors within tumor stroma.
The speakers will here address the conflicting results on the role of MSC in cancer in parallel suggesting the role of MSC in inducing cancer death. The latest findings in the field will be presented opening novel roles of MSC in oncology and hematology.
________________________________________
Workshop 3: Antigen Specific T Cells
Thursday 5/19/2011
Time: 3:30pm – 5:00pm

Adoptive immunotherapy is emerging as a safe alternative to chemotherapeutic drugs for both viral infections and relapsed malignancies after hematopoietic stem cell transplantation (SCT). Despite showing efficacy against virus infection in numerous clinical trials, the lack of in vivo persistence of transferred T cells and their unproven effectiveness against various malignancies are challenges that have yet to be overcome. To date, most if not all adoptively transferred antigen-specific T cells have been derived from memory T cells. Therefore, virus-specific T cells –though shown to be effective for recipients of virus experienced donors- are unavailable for SCT recipients of cord blood or virus-seronegative donor grafts. Pre-clinical data on human antigen-specific T cells generated from naïve T cells has been scant and mostly limited to EBV or OKT3-stimulated T cells bearing exogenous TCRs. At this workshop session we will now present novel developments (both preclinical and clinical) demonstrating that antigen-specific T cells can be generated from human naïve T cells using GMP compliant technologies. In addition to viral infection, leukemic relapse remains a significant cause of SCT treatment failure. Hence, there is a need to develop additional strategies to enhance the graft versus leukemia (GVL) effect. New approaches to improve the GVL effect including vaccines to prime and boost leukemia specific T cells and adoptive transfer of ex vivo expanded leukemia specific cytotoxic T cells (CTL) will also be discussed at this session.
________________________________________
Workshop 4: How to improve in vivo vascularisation (Joint Session with TERMIS-EU)
Friday 5/20/2011
Time: 3:30pm – 5:00pm

When a tissue engineered construct is implanted in the body, survival of cells is a key point. Slow vascularisation of the graft is one of the major problems. There are different possible ways to improve vascularisation after implantation. In this symposium different approaches to obtain rapid vascularisation by engineering of new vessels in constructs will be discussed. We will make use of an automatic voting system and encourage discussion with challenging statements to have the audience actively involved.
Includes a structured discussion at the end (approximately 30 minutes)
________________________________________
Workshop 5: Dendritic Cells
Friday 5/20/2011
Time: 3:30pm – 5:00pm

Following Provenge’s FDA approval for DC vaccines on prostate cancer there is again an increasing scientific interest in clinical use of DC against cancer. Over the last 10 years many centers around the world have been working with DC vaccines. Most of these studies have been small non- randomized studies treating patients with resistant metastatic disease. Unfortunately, the success rate with DC vaccines has been highly variable with clinical responses between 0-20%. The reasons for these effects are multi-factorial and can not be explained only by the type of patients offered DC vaccines. This workshop will discuss which subtype of DC should be used, how to mature the DC in vitro, which antigen should be targeted in vivo, the route of administration of DCs, dose of DCs, frequency and duration of DC vaccination. Finally methods to break tolerance in vivo to improve clinical effects of DC vaccination will also be discussed.
________________________________________
Workshop 6: New Gene Transfer Technologies (Joint Session with ESGCT)
Saturday 5/21/2011
Time: 1:15pm – 2:45pm

Pivotal to the success of genetic engineering of therapeutic cells (e.g., immune effector cells; human stem/progenitor cells) is the availability of adequate gene transfer technologies, comprising both virus and non-virus based transfer methods. To date, retro-/lentiviral gene transfer is most wide spread in clinical applications, but bears drawback of ad random genomic integration with related safety concerns and gene silencing by host restriction factors. In this workshop we present promising new developments in both non-viral and viral gene therapy, including transposon-based methods (Dr. Izsvák), site specific gene editing using zinc finger nucleases (Dr. Rahman) as well as new developments in viral gene transfer (Dr. Rethwilm). In addition prospects of translation to clinical application will be discussed.
________________________________________
Workshop 7: Lung Regeneration
Saturday 5/21/2011
Time: 1:15pm – 2:45pm

Many lung diseases remain incurable or have poor therapeutic options. New approaches using both embryonic and adult stem cells provide new potential therapeutic options and are expected to be an area of rapid translational and clinical growth. Following an overview of the current state of the field, specific focus areas to be discussed will include immunomodulation of lung diseases by mesenchymal stromal cells (MSCs), clinical trials with MSCs and endothelial progenitor cells, cell therapy approaches for lung cancer, and bioengineering new lungs utilizing stem cells.

Milton Artur Ruiz

17th ISCT Annual Meeting– Rotterdam – Nedherland 2011 – Sessões Técnicas

As sessões do ISCT Annual Meeting buscam discutir temas específicos de Terapia celular. Na seqüência apresento vários destes temas que poderão ser discutidos ou pontuados no futuro em seus aspectos mais relevantes. Abaixo encontra-se um sumário disponibilizado pela organização do evento e que estão disponíveis de forma temporária no site www.cellulartherapy2011.com

Sessões Técnicas
Technical Session 1: Imaging Cell Therapy
Thursday 5/19/2011
Time: 7:45am – 8:45am

The possibility of isolating and expanding stem cells and of driving them towards various phenotypes have motivated exploration and development of stem cell based therapy. In order to understand the mechanism, and to improve the efficacy of these treatment approaches, the monitoring of the fate and biodistribution of the transplanted cells is necessary. The current non-invasive techniques of the in vivo tracking of stem cells include direct labeling with magnetic particles for magnet resonance imaging or radionuclides for scintigraphic or positron emission computer tomography (PET), and indirect labeling with reporter genes, such as PET, fluorescence, or bioluminescence reporter gene methods. The present session summarizes these techniques, mentioning their particular advantages and usefulness under experimental and clinical conditions in the context of bone and cardiac tissue engineering.
________________________________________
Technical Session 2: Practical Considerations in Cell Selection for Cellular Therapy
Thursday 5/19/2011
Time: 7:45am – 8:45am

Cell selection methods for cellular therapy are generally first optimized for use in small animal models. In most cases cell selection involves magnetic particle cell sorting, high-speed droplet sorting, or a combination of these two technologies. Each technology requires optimized cell labeling protocols to reliably obtain the cell population of interest. In preparation for clinical trials these methods often need changes to accommodate testing in humans. Moreover, the increasingly complex phenotypic description of therapeutic cell populations has made high-speed droplet sorting the cell selection method of choice in many research settings. High-speed droplet sorting in particular brings a series of challenges when used in the clinic, presenting investigators with the dilemma to either overcome the challenges or to switch to magnetic particle cell sorting. This session is also intended to facilitate sharing information about what works and what doesn’t in cell selection methods for cellular therapy in the clinic. Topics to discuss include: scaling up (antibody usage, duration of the process), logistics, clinical grade antibodies, sterility, controls, safety and regulatory requirements.
________________________________________
Technical Session 3: Potency Assays in stem cell based therapeutics
Friday 5/20/2011
Time: 7:30am – 8:30am

A biological measurement of the activity of a cell product is the most critical step in the product release for both clinical trials as well as market-placed products.
The session will present you some intriguing applications of two of the most popular techniques currently used for cell product characterization: flow cytometry and microarray analysis. Dr. de Boer will present a biopotency assay on mesenchymal stromal cells used for bone tissue engineering. In fact, large differences exist in bone forming efficacy between MSCs isolated from different donors, but no proper in vitro marker is known which predicts the in vivo bone forming capacity of a given donor. He will present the use of microarray analysis to correlate the in vitro gene expression profile of MSCs of different donors with their potency to form bone in an immune-deficient mouse model and identified CadM1 as a highly predictive classifier. The presentation by Dr. Moro will give you a general overview on how to use flow-cytometry to identify the phenotypic characteristics that corresponds to the target functional stem cell population. Examples will be given in the context of hematopoietic as well as mesenchymal stem cell applications.
________________________________________
Technical Session 4: ES/iPS Cells
Friday 5/20/2011
Time: 7:30 am – 8:30 am

Two kinds of pluripotent stem cells exist, embryonic stem (ES) cells and induced pluripotent stem (iPS) cells, which are somatic cells that acquired pluripotency by the expression of specific factors. Since these cells can be maintained in culture indefinitely without losing the ability to generate all cell types of a human body, they provide unique opportunities to regenerative medicine, fundamental research and drug or toxicity testing. In addition, the unlimited self-renewal features allow the establishment of banks of pluripotent stem cell lines covering most frequent haplotypes. In this session an overview of the latest progress on the use of iPS cells for treating blood disorders, and on the banking of pluripotent stem cells for research and clinical purposes will be presented.
________________________________________
Technical Session 5: Adipose Mesenchymal Progenitors
Saturday 5/21/2011
Time: 7:30am – 8:30am

The greatest interest of adipose tissue as a source of therapeutic cells is the fact that there is no ethical concern about this source since it is obtained from an adult, is abundant and easy to get tissue, even when compared with bone marrow, sampling of which requires more invasive technique. Another advantage is that, as the frequency of Adipose Derived Stromal Cells is much higher in adipose tissue than those of MSC in bone marrow, a large number of cells can be obtained without a large number of passages. In this way, the risk of culture-induced chromosomal abnormality senescence is largely decreased. On the other hand, a key step in the process of isolation of adipose derived immature cells is the digestion of the tissue and the choice of protocols that can lead to isolate different cell subsets. This step and the need of the adequate protocol for their in vitro culture expansion is crucial for the security and the efficiency of their therapeutic uses. This session deals with these different points that represents a key stake for adult stem cell based regenerative medicine.
________________________________________
Technical Session 6: Ancillary Materials
Saturday 5/21/2011
Time: 7:30am – 8:30am

Quality of the components used in the manufacturing of cellular or tissue-based therapies will have great impact on the quality of finished products. Examples of these components include the source cells and tissues, biomaterials, ancillary materials, and excipients used in the formulation of cellular or tissue-based therapies. Ancillary materials are biological/biochemical substances which play an important role in the manufacture of cellular therapies and also in the manufacture of other therapeutics using living cells in their processes. To ensure quality of finished goods, it is important that qualification programs are in place, for the assessment of these ancillary materials. The scope of this session is to highlight the different quality aspects that relate to the manufacture of somatic cell therapy and tissue-engineered products, including a discussion on how the performance of reagents can be evaluated through the use of materials with acceptable test specifications.

Milton Artur Ruiz

17th ISCT Annual Meeting– Rotterdam – Nedherland 2011 – Sessões plenárias

Sessões PlenáriasAs sessões plenárias do Congresso da ISCT são as mais concorridas do evento por não ter coincidência com outra atividade do evento.
Abaixo serão colocadas todas que dispõem de texto realizado pelo próprio autor e disponibilizadas no site já citado anteriormente. www.celltherapy2011.org

Plenary Session 1: Presidential Plenary on Mesenchymal Stem Cells
Thursday 5/19/2011
Time: 9:00am – 10:30am

Chair: Edwin Horwitz

MSCs: Current Clinical Applications and Future ChallengesArmand Keating (Canadá)

In this talk the author discuss actual results and the future of cell therapy pointing the difference of replacement therapy and treatment with cell therapy. It was present many results in those fields that he considered very promising

Text by Mlton Artur Ruiz.

MSC from genetic stability to controls of safetyLuc Sensebé ( França)

In recent years, relevant data have indicated that mesenchymal stromal/stem cells (MSC) can be used as reparative/regenerative cells to treat a range of clinical conditions including immunological disorders as well as degenerative situations. A major safety concern is the genomic stability of mesenchymal stromal cells particularly related to the risk of cell transformation. As during ageing, cell expansion might be associated with replicative senescence, replicative stress, mutations, chromosomal abnormalities and other stochastic cell defects that could progressively alter cells and have to be investigated. Replicative senescence arises through different well known mechanisms such as telomere shortening, activation of pRB pathway through INK4a/ARF locus encoding p16ink4a and p19ink4a, and activation of p53 pathway (Krishnamurthy 2004, Campisi & d’Adda di Fagagna 2007). As previously demonstrated MSCs transformation is a rare, long, multistep process (Serakinci et al., 2004, Prockop et al, 2010). Recently, we showed that clinical-grade–cultured human MSCs, regardless of the presence of aneuploidy, reached senescence and never transformed (Tarte et al., 2010). However, the main control still used for the release of GMP clinical grade MSC remains karyotype that appears neither sufficient nor sensitive enough. To understand the changes and risks induced by culture process, it is mandatory to more deeply analyze genetic perturbations, not only the main molecules of replicative senescence checkpoint (p53, p21, p16, p19 and pRB) but also at a more subtle level defective DNA replication program, which has been shown as anticipating most gross cancer-associated genetic changes. Molecular targets involved in genetic stability of MSC should be defined to develop reliable quality controls for production of safe MSC according to GMP.
• Campisi J & d’Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol. 2007 ; 8 :729-740
• Krishnamurthy J, Torrice C, Ramsey M.R,Kovalev G.I, Al-Regaiey K, Su L, Sharpless N.E. Ink4a/Arf expression is a biomarker of aging. J. Clin.Invest. 2004, 114:1299-1307
• Prockop DJ, Brenner M, Fibbe WE, Horwitz E, Le Blanc K, Phinney DG, Simmons PJ, Sensebe L, Keating A (2010). Defining the risks of mesenchymal stromal cell therapy. Cytotherapy 12:576-578
• Serakinci N, Guldberg P, Burns JS, Abdallah B, Schrodder H, Jensen T et al (2004). Adult human mesenchymal stem cell as a target for neoplastic transformation. Oncogene 23: 5095-8.
• Tarte K, Gaillard J, Lataillade JJ, Fouillard L, Becker M, Mossafa H et al (2010). Clinical-grade production of human mesenchymal stromal cells: occurrence of aneuploidy without transformation. Blood 115: 1549-53.

MISOT – Mesenchymal Stem Cells in Solid Organ Transplantation
Marc Dahlke

Solid organ transplantation provides the definitive treatment for many end-stage diseases. However, life-long immunosuppression needed to prevent graft rejection causes clinically significant side effects. In fact, the overall success of solid organ transplantation as a curative therapy often depends on the occurrence and management of drug side effects. Cellular immunomodulatory therapies with MSC may therefore be suitable to reduce the dose of immunosuppressive drugs.
The MISOT study group has brought European investigators together and a variety of protocols to complement immunosuppressive pharmacotherapy with MSC have been suggested. To decide if patients undergoing organ transplantation can be safely treated with MSC and if these therapies yield a benefit for patient and graft survival, careful consideration of all available preclinical and clinical data has to be carried out.
________________________________________
Plenary Session 2 – Regenerative Medicine and Tissue Engineering
Thursday 5/19/2011
Time: 1:45pm – 3:15pm

Cartilage tissue engineering: are we ready to translate into the clinic?
Anthony Hollander

Tissue engineered cartilage may be used to treat degenerative joint diseases such as osteoarthritis as well as diseases in other cartilaginous structures such as the airway. Knowing when we are ready to take our science out of the laboratory and into the clinic is a key problem for the tissue engineer. Articular cartilage repair using chondrocytes has been in widespread use for 20 years but using stem cells to create engineered cartilage that can be implanted into the joint as a mature tissue has not yet been considered ready for translation. Development of a more robust and predictable outcome of cartilage tissue engineering may help to provide the confidence need to use such implants therapeutically. Meniscal cartilage repair has not received as much research attention as articular cartilage and yet it is a significant medical problem with no therapy available other than removal of the torn tissue, resulting in a high risk of subsequent osteoarthritis. Stem cells may provide a good opportunity for a new approach to this old problem. Airway stenosis does not affect large numbers of patients but it can be life-threatening. Replacement of a severely damaged bronchus with tissue engineered trachea in one patient has shown the potential for whole organ replacement in the future. Each of these examples will be considered as an illustration of the complexity of knowing when we are ready to turn science into medicine.

Challenges in 3D tissue graft manufacturing
Ivan Martin

Despite the compelling clinical need to regenerate damaged tissues/organs, impressive advances in the field of tissue engineering have yet to result in viable engineered tissue products with widespread therapeutic adoption. The main challenges to be overcome have been identified in the yet not convincing benefit of the proposed therapies, combined with their high costs. Following the exemplifying paradigm of bone and cartilage regeneration, the lecture will highlight the bottlenecks of typical manufacturing strategies and will propose alternative bioreactor-based approaches for the manufacturing of 3D cellular grafts. The perspective will address issues related to quality standardization, process control and regulatory compliance in manufacturing cell-based products and highlight the need not only to automate, but also to streamline and simplify typical production processes. Examples will be given on the attractive paradigm to expand mesenchymal stem/progenitor cells from adult individuals directly in a “3D niche” environment, thereby maintaining a larger post-expansion differentiation capacity and bypassing the complex and costly serial cell passaging in monolayers. Finally, as a next generation paradigm, the lecture will propose and exemplify the concept of engineering regenerative strategies following principles of developmental biology, using the own body as the in vivo bioreactor.

Smart materials for programming stem cell fate in situ
Matthias Lutolf

A complex mixture of extracellular cues delivered by support cells is critical for adult stem cell maintenance and the regulation of self-renewal in their microenvironment, termed niche. Despite recent progress in the identification of relevant niche proteins and signaling pathways in mice, to date, many adult stem cell populations cannot be efficiently cultured in vitro without rapidly differentiating.
In this talk I will highlight recent efforts in my lab to develop and apply novel in vitro culture paradigms that allow fate decisions of hundreds of individual adult stem cells to be monitored under well-controlled conditions and in real time. For example, we have engineered microarrayed ‘artificial niches’ for hematopoietic stem cells (HSC) based on a combination of biomolecular hydrogel and microfabrication technologies that allow key biochemical characteristics of niches to be mimicked and the physiological complexity deconstructed into a smaller, experimentally amenable number of distinct signaling interactions. We have also built and applied microfluidic chips to sequentially capture single HSC after multiple divisions to assess their fate, and in particular the symmetry of division, by multigene single cell qRT-PCR.
The systematic deconstruction of a stem cell niche may serve as a broadly applicable paradigm for defining and reconstructing artificial niches to accelerate the transition of stem cell biology to the clinic.
________________________________________
Plenary Session 3 – Cardiovascular Cell Therapy
Friday 5/20/2011
Time: 8:45am – 10:15am

Repair by bone marrow-derived cells: experimental and clinical insights
Douglas Losordo

Synopsis not available.

Human iPSC models of cardiac disease
Karl-Ludwig Laugwitz

Much of what is known about the molecular pathways that lead to human cardiovascular disorders has come from studying animal models, particularly genetically modified mice. In some cases it is possible to translate genetic discoveries from humans to mice (e.g. non-sense mutations), but in most circumstances there are no direct correlates for human genetic variants such as single nucleotide polymorphisms (SNPs) or copy number variants. Therefore, it is imperative to replicate relevant features of human cardiovascular physiology in the context of the human genome. Recent advances in stem cell biology now raise the possibility of generating human models of cardiovascular physiology and disease.
Generating patient-specific cells and tissues has recently emerged with the demonstration that exogenous expression of four proteins in human skin fibroblasts (e.g. c-MYC, KLF4, OCT4, and SOX2) is sufficient to induce pluripotency in the cells. Although so-called induced pluripotent stem cells (iPSCs) are not perfectly equivalent to human ES cells, they retain important properties of ES cells such as the capacity for long-term propagation and the ability to differentiate into all human somatic cell types. Factor-based reprogramming enables us of the long-standing ambitions of stem cell biology: the ability to generate pluripotent cells from specific patients and figuratively, move a patient`s disease into the Petri dish. This will be discussed for human monogenetic cardiovascular diseases, e.g. LQT syndromes, catecholaminergic polymorphic ventricular tachycardia (CPVT) and arrhythmogenic right ventricular dysplasia (ARVC).
Recent advances describing the derivation of human iPSCs from peripheral, frozen blood brings the stem cell field an important step closer to bio-banked blood samples and eventual clinical use.
Moretti A, Bellin M, Welling A, Jung CB, Lam JT, Bott-Flügel L, Dorn T, Gödel A, Höhnke C, Hofmann F, Seyfarth M, Sinnecker D, Schömig A & Laugwitz K-L (2010). Patient-specific induced pluripotent stem cell models for long-QT syndrome. N Engl J Med., Epub Jul 21.

microRNAs in cardiovascular repair
Stefanie Dimmeler

MicroRNAs (miRs) are small non-coding RNAs, which control gene expression by either inducing mRNA degradation or by blocking translation, and play a crucial role in tissue homeostasis. In the cardiovascular system, miRs were shown to control cardiac hypertrophy, fibrosis and apoptosis, angiogenesis and vessel remodeling. In addition, miRs regulate stem cell maintenance and some miRs induced cell fate decisions. The presentation will provide an overview of involvement of miRs in cardiovascular lineage commitment and cell function. Particularly, the regulation and function of miRs in bone marrow derived cells that are used for cell therapy of cardiovascular diseases will be discussed.
________________________________________
Plenary Session 4 – T Cell ImmunotherapyFriday 5/20/2011
Time: 1:45pm – 3:15pm

Alloreactive T cells for the treatment of leukemia
Fred Falkenburg

Allogeneic hematopoietic stem cell transplantation allows the exploration of cellular immunotherapy strategies. Following engraftment of donor hematopoiesis in the patient, donor derived alloreactive T cells are capable of eliciting both graft versus host disease (GVHD) and graft versus leukemia (GVL) reactivity. Separation of immune responses resulting in GVHD from those involved in GVL reactivity is essential for improving the outcome of stem cell transplantation for hematological disorders.
T cell responses directed against polymorphic antigens expressed on normal non-hematopoietic tissues of the recipient are likely to be responsible for severe GVHD. In contrast, alloreactive donor derived T cell directed against antigens preferentially expressed on cells of hematopoietic origin may lead to profound reactivity against normal and malignant hematopoietic cells of recipient origin while preserving hematopoiesis of donor origin and sparing of patient derived non-hematopoietic tissues thereby limiting GVHD. Donor derived CD8 T cell responses directed against antigens recognized in the context of HLA class-I molecules will lead to strong cytotoxicity against target tissues. Since HLA class-I molecules are broadly expressed on most tissues, only CD8 T cells recognizing HLA class-I bound peptides derived from hematopoiesis specific proteins have been considered appropriate candidates for specific anti tumor reactivity after transplantation. However, not all T cell reactivity against antigens expressed on non hematopoietic tissues may lead to severe GVHD. The cellular activation state influenced by inflammatory circumstances in the non hematopoietic tissues is an essential factor in the ability of T cells to damage these tissues.
Since HLA class-II molecules show a more restricted tissue distribution, T cell responses against antigens presented in HLA class-II may also lead to relatively specific GVL responses. T cell responses recognizing antigens in the context of HLA-DQ and HLA-DP have been found to be associated with anti tumor effects with limited GVHD. However, inflammatory circumstances in the recipient may lead to upregulation of HLA class-II molecules on non-hematopoietic tissues resulting in GVHD. These results illustrate that both the specificity of the T cell responses, and the inflammatory environment will determine the balance between GVHD and GVL reactivity after allogeneic hematopoietic stem cell transplantation.

Dissection of cell therapy-induced cytotoxic T cell responses in melanoma
Ton Schumacher

There is strong evidence that melanoma-reactive T cell responses induced by immunotherapeutic interventions such as anti-CTLA4 treatment or T cell therapy with tumor-infiltrating lymphocytes (TIL) can exert clinically meaningful effects. However, at present we do not know which cytotoxic T cell reactivities mediate cancer regression. Furthermore, as the number of potential melanoma-associated antigens to which these responses can be directed is very high, classical strategies to map cytotoxic T cell reactivity do not suffice. Knowledge of such reactivities would be useful to design more targeted strategies that selectively aim to induce immune reactivity against these antigens.
In the past years we have aimed to address this issue by designing MHC class I molecules occupied with UV-sensitive ‘conditional’ peptide ligands, thereby allowing the production of very large collections of pMHC complexes for T cell detection. Secondly, we have developed a ‘combinatorial coding’ strategy that allows the parallel detection of dozens of different T cell populations within a single sample. The combined use of MHC ligand exchange and combinatorial coding allows the high-throughput dissection of disease- and therapy-induced CTL immunity. We have now used this platform to monitor immune reactivity against a panel of over 200 melanoma-associated epitopes. Data on the composition of TIL products used for adoptive cell therapy and on the effect of TIL therapy on the tumor-reactive T cell repertoire in melanoma patients will be presented.
Translation of immunotherapy using WT1 and CMV specific TCR gene transfer into the clinic
Emma Morris
Adoptive transfer of antigen-specific T cells is an effective form of immunotherapy for persistent virus infections and cancer. Major limitations of adoptive therapy are the inability to isolate antigen-specific T cells reproducibly and expand them to sufficient numbers ex vivo, whilst maintaining optimal function and specificity.
We and others have developed gene therapy approaches to overcome the problems related to poor tumour immunogenicity and lack of specificity of allogeneic T cell therapy. Retroviral gene transfer can generate large numbers of high avidity antigen-specific T cells. Retroviral transfer of cloned T cell receptor (TCR) genes reliably re-directs the antigen specificity of T cells. We have exploited the allo-reactive T cell repertoire to isolate high avidity T cells specific for the tumour-associated antigen WT1, which is highly expressed in MDS, AML, CML and ALL, together with a number of solid tumours. The genes encoding the T cell receptor of the WT1-specific, allo-restricted T cells were isolated and inserted into retroviral vectors for gene transfer into primary human T cells. In vitro, the gene modified T cells can kill primary human leukaemia cells and also autologous leukaemia cells expressing WT1 endogenously. Following adoptive transfer they can protect against the growth of autologous primary leukaemia cells in the xenogeneic NOD/SCID model. We can now manufacture GMP grade WT1 TCR-transduced T cells and aim to recruit patients into a Phase I study this year.
Reactivation of the latent human herpes virus, Cytomegalovirus (CMV) post allogeneic haematopoietic stem cell transplantation (Allo-HSCT) can result in significant morbidity and mortality unless treated promptly. Anti-viral therapy is usually effective, but has serious side effects, such as myelosuppression (Ganciclovir) or nephrotoxicity (Foscarnet). Cellular immunotherapy for CMV has been tested in Phase I/II trials in the UK and Europe. In these trials CMV-specific T cells were isolated from the peripheral blood of CMV seropositive donors and re-infused into recipients following CMV reactivation resulting in sustained anti-viral responses. It is clear that post-transplant recovery of CD8+ CMV-specific cytotoxic T-cells (CTL) abrogates the development of CMV-related disease. An advantage of cellular therapy for CMV reactivation is the transfer of immunological memory, which can reduce the number of subsequent reactivations. We have used TCR gene transfer to generate CMV pp65-specific T cells from donors who are CMV seronegative (therefore lack CMV-specific T cells), where the transplant recipient is CMV seropositive and at risk of CMV reactivation post transplant. Both CD8+ and CD4+ T cells expressing the MHC class I-restricted TCR display CMV-specific effector function in vitro and in vivo.
________________________________________
Plenary Session 5 – Cancer Stem CellsSaturday 5/21/2011
Time: 8:45am – 10:15am

Cancer stem cells from colorectal cancer cell linesSir Walter Bodmer

Colorectal cancer is one of the best defined cancers from a genetic point of view, both at the germ line and somatic levels. We work with a panel of more than 100 colorectal cancer derived cell lines that are extensively characterised with respect to their genetic/epigenetic make up and for whole genome mRNA expression. The lines provide invaluable models for studying the biology and somatic genetics of colorectal cancers, and enable in vitro investigation of the properties of colorectal cancer stem cells. We now can characterise the driving cancer stem cells in these lines and begin to identify the factors that control their differentiation, in particular, through having shown that hypoxia(1% oxygen) inhibits cancer stem cell differentiation in vitro.

Lgr5 Intestinal Stem Cells in self-renewal and cancerMarc van de Wetering

The intestinal epithelium is the most rapidly self-renewing tissue in adult mammals. Current models state that 4-6 crypt stem cells reside at the +4 position immediately above the Paneth cells in the small intestine; colon stem cells remain undefined. Lgr5/Gpr49 was selected from a panel of intestinal Wnt target genes for its restricted crypt expression. Two knock-in alleles revealed exclusive expression of Lgr5 in cycling, columnar cells at the crypt base. In addition, Lgr5 was expressed in rare cells in several other tissues. Using an inducible Cre knock-in allele and the Rosa26-LacZ reporter strain, lineage tracing experiments were performed in adult mice. The Lgr5+ve crypt base columnar cell (CBC) generated all epithelial lineages over a 14 month period, implying that it represents the stem cell of the small intestine and colon. The expression pattern of Lgr5 suggests that it marks stem cells in multiple adult tissues and cancers.
We have now established long-term culture conditions under which single crypts undergo multiple crypt fission events, whilst simultanously generating villus-like epithelial domains in which all differentiated cell types are present. Single sorted Lgr5+ve stem cells can also initiate these crypt-villus organoids. Tracing experiments indicate that the Lgr5+ve stem cell hierarchy is maintained in organoids. We conclude that intestinal crypt-villus units are self-organizing structures, which can be built from a single stem cell in the absence of a non-epithelial cellular niche.
Intestinal cancer is initiated by Wnt pathway-activating mutations in genes such as APC. As in most cancers, the cell of origin has remained elusive. Deletion of APC in in Lgr5+ve stem cells leads to their transformation within days. Transformed stem cells remain located at crypt bottoms, while fueling a growing microadenoma. These microadenomas display unimpeded growth and develop into macroscopic adenomas within 4-6 weeks. When APC is deleted in short-lived Transit Amplifying (TA) cells using a different Cre mouse, the growth of the induced microadenomas rapidly stalls. Even after 30 weeks, large adenomas are very rare in these mice. We conclude that stem cell-specific loss of APC results in progressively growing neoplasia. Moreover, a stem cell/progenitor cell hierarchy is maintained in early stem cell-derived adenomas, lending support to the “cancer stem cell”-concept.

Modeling Colon Stem Cells and Neoplasia Using Primary Explant Cultures Containing an Endogenous Wnt-dependent NicheCalvin Kuo

The intestine undergoes continuous epithelial regeneration that absolutely requires ongoing Wnt signaling. We have developed in vitro culture systems that enable long-term propagation and multi-lineage differentiation of intestinal epithelium and allow sustained intestinal proliferation, multi-lineage differentiation and the support of Lgr5+ and Bmi1+ intestinal stem cells (ISC) over a range of 30 to > 350 d. The defining characteristics of this approach include (1) culture of intestinal epithelium within an air-liquid interface coupled with a 3D culture matrix and (2) the use of explant tissue that include stromal myofibroblasts, neural elements, and recapitulate endogenous peristalsis. Notably, growth does not require the addition of exogenous Wnt agonists, as fetal calf serum alone is sufficient, and growth is ablated by recombinant Dkk1, indicating the presence of endogenous Wnt signaling within the explant cultures. This system recapitulates both the cellular architecture and the rigorous Wnt- and Notch- dependency of the intestinal stem cell niche, and applications to the modeling of colon cancer will be discussed.
________________________________________
Plenary Session 6 – Embryonic to Adult Stem CellsSaturday 5/21/2011
Time: 2:55pm – 4:25pm

Origin of mesenchymal stem cellTakumi Era

Mesenchymal stem cell (MSC) is defined by their ability both to undergo sustained proliferation in vitro and to give rise to multiple mesenchymal cell lineages including bone, cartilage, and fat cells. Although MSCs are a demonstrated reality with applications in regenerative medicine, not much is known about their in vivo characteristics, such as their developmental derivation. Recently we found the new the developmental pathway of MSC during mouse embryogenesis. Using in vitro ES cell culture, we have shown that Sox1+ neuroepithelial cells generate MSCs at the highest efficiency. ES cell-derived day 9 PDGFRa+ precursors induced by RA treatment morphologically exhibit fibroblastic and undergo the self-renew in vitro with maintaining the potential to give rise to multiple lineages including bone, cartilage, and fat cells. Interestingly, the PDGFRa+ cells are derived not from mesoderm cells but from neuroepithelium cells in our ES cell culture. This unexpected result suggests that the neuroepithelium is a candidate of embryonic origin of MSCs. To confirm this result in actual embryo, we are proceeding to search for the origin of MSCs in vivo using genetically fate-trucking method. In E9.5 embryos, we could induce MSCs from Sox1+ cells but not from PDGFRa+ mesoderm. While this type of MSC is found also in neonatal bone marrow at low frequency, most MSCs in postnatal bone marrow are derived from other origins, which are also enriched in the PDGFRa+ population. Thus, we show that MSCs are generated from multiple sources, with those derived from neuroepithelium constituting the earliest wave.

The development of hematopoietic stem cells: Endothelial to hematopoietic transitionElaine Dzierzak

Hematopoietic stem cells (HSC) are the source of all blood cells in the adult. The first HSCs are generated in the aorta-gonad-mesonephros (AGM) region at midgestation in the mouse embryo and at week 4-6 in human gestation. AGM HSCs are generated following the anatomical appearance of clusters of hematopoietic cells closely associated with the lumenal wall of aorta and vitelline/umbilical arteries. The relationship of HSCs to these clusters and the identification of the precursors to HSCs is an area of intense research focus. To begin to understand how clusters are formed we have developed a 3-dimensional whole mount immunostaining and confocal imaging method by which we can temporally map and quantitate all hematopoietic clusters in normal (and hematopoietic defective) mouse embryos (Yokomizo and Dzierzak, Development, 2010). We have localized HSC activity to the hematopoietic clusters. Visual proof that HSCs arise from aortic endothelium comes from time lapse vital imaging of the AGM (Boisset et al., Nature, 2010). Remarkably, HSCs arise directly from endothelial cells of the dorsal aorta in a natural transdifferentiation event. HSC generation is regulated through ventral-derived developmental signals and a group of pivotal (core) transcription factors, including Runx1 and Gata2. Knockout strategies implicate these factors in hematopoietic fate induction and/or expansion. These transcription factors are required for the generation of vascular hematopoietic clusters and HSCs. Developmental signalling pathways triggered by BMP4 and Hedgehog, appear to act upstream of these transcription factors.

Vários dos temas aqui apresentados serão discutidos posteriormente.

Milton Artur Ruiz

VI Congresso Brasileiro de Células tronco e Terapia Celular

Este ano o Congresso Brasileiro de Células-tronco e Terapia celular será realizado de 28 de Setembro a 01 de Outubro no Hotel Stella Maris em Salvador na Bahia
Informações poderão ser obtidas diretamente no site do evento
http://www.interlinkeventos.com.br/celulastronco2011/index.html

Inscrições de trabalhos científicos no Pan-Amazônico

O III Congresso Pan-Amazônico e IV de Encontro Anual do Comitê de Glóbulos Vermelhos e do Ferro, acontecerá nos dias 26 e 27 de maio em Belém (PA). No evento será realizado uma apresentação de trabalhos científicos na forma de “posters”.
Com uma grade científica multidisciplinar, o encontro está estimando a presença de mais de mil congressistas, entre hematologistas, hemoterapeutas e profissionais de enfermagem, biomedicina, farmácia, bioquímica, odontologia, fisioterapia, psicologia, assistência social e de gestão do Norte e demais regiões do Brasil.
Os resumos par os posters poderão ser enviados até o dia 25 de abril. Confira o regulamento para a submissão dos resumos no portal do encontro www.panamazonico.com.br O melhor trabalho será aquinhoado com o Prêmio João Carlos Pina Saraiva recém instituído pela ABHH.
Estas e outras informações estão disponíveis no site www.newsabhh.com.br da Associação Brasileira de Hematologia e Hemoterapia (ABHH).
Milton Artur Ruiz

Sobre o Autor

Médico, Hematologista, Hemoterapeuta, Professor Colaborador da disciplina de Hematologia/Hemoterapia da Faculdade de Medicina da Universidade de S. Paulo, USP-SP, Coordenador do Grupo de Estudos de Terapia celular do IMC de S J do Rio Preto-SP, Chefe da Unidade de Transplante de Medula Óssea do Hospital Infante D. Henrique da Associação Portuguesa de Beneficencia de SJ do Rio Preto SP. , Editor da Revista Brasileira de Hematologia e Hemoterapia - Journal of Hematology and Hemotherapy ISSN 1516 8494 , Mestre em Hematologia – Escola Paulista de Medicina, Unifesp-SP, Doutor em Medicina Interna – Unicamp-SP, Livre docente em Hematologia- Famerp- SP.

Está no seu momento de descanso né? Entao clique aqui!